

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Thomas, David et al.

Serial No.: 09/773866

Filed: February 1, 2001

For: CD40-BINDING APC-ACTIVATING

MOLECULES

Attorney Docket No.: PNJ-001

Group Art Unit: 1644

Examiner: Gambel, Phillip

RECEIVED

nrt 1 5 2003

OFFICE OF PETITIONS

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Airbill No. EV 309882782 US in an envelope addressed to: MS Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

tber 10.2003

Date of Signature and of Mail Deposit

By:

Cynthia L. Kanik, Ph.D.

Reg. No. 37,320

Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following additional publications, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

10/15/2003 RELANCO 0000008 120080 09773866

130.00 DA 3001:31 90

relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Respectfully submitted, LAHIVE & COCKFIELD, LLP

Cynthia L. Kanik, Ph.D. Registration No. 37,320 Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

JER/CLK/alf Enclosures RECEIVED

OCT 1 5 2003

OFFICE OF PETITIONS.

Sheet 1 of 1

APPLICANT FACSIMILE OF FORM REV 7-80	TEN & TRADE

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO	SERIAL NO.
PNJ-001	09/773866
APPLICANT	
Thomas, David et al.	
FILING DATE	GROUP
February 1, 2001	1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	Country	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
D1	WO 99/61065 A1	12/99	WO				
D2	WO 02/11763 A1	2/02	WO				

		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)
	D3	Bjorck et al. "Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40." Immunology. 1994 Nov;83(3):430-7
1	D4	Heath et al. "Monoclonal antibodies to murine CD40 define two distinct functional epitopes." Eur. J. Immunol. 1994 Aug;24(8):1828-34
	D5	Holder et al. "Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction." Eur. J. Immunol. 1993 Sep;23(9):2368-71
	D6	Pellat-Deceunynck et al. "CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation." Cancer Res. 1996 Apr 15;56(8):1909-16
		Schwabe et al. "Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies." Hybridoma. 1997 Jun;16(3):217-26
	D8	Valle et al. "Activation of human B lymphocytes through CD40 and interleukin 4." Eur. J. Immunol. 1989 Aug;19(8):1463-7
		RECEIVED
		OCT 1 5 2003
		OFFICE OF PETITIONS
Examine	er	Date Considered
*EXAMII	NER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through

applicant.